Manu Raj Pandey

PO-02-026 COMPARATIVE RISK OF ATRIAL FIBRILLATION AND CARDIOVASCULAR OUTCOMES WITH ZANUBRUTINIB VS IBRUTINIB IN B-CELL MALIGNANCIES: A LARGE REAL-WORLD PROPENSITY-MATCHED ANALYSIS

Usama Qamar, Muhammad Hassan Jan, Siddharth Agarwal, Muhammad Bilal Munir et autres

Sequential Bispecific Antibodies and CAR-T Use Is a Safe and Effective Strategy in Relapsed Refractory Hematologic Malignancies

Aqsa Ashraf, Bibi Arifa, Noha Soror, Dr. Muhammad Salman Faisal et autres

Introduction Chimeric antigen receptor T cell (CAR-T) therapy has transformed the management of relapsed/refractory (R/R) hematologic malignancies. Prolonged use of bispecific antibodies (BsAb) provides effective T cell based immunotherapy but may induce T cell exhaustion, cross resistance, and increased toxicity, potentially impacting …

us (code pays fourni par la source)

Optimizing Natural Killer Cellular Therapy in Acute Myeloid Leukemia

Binsah George, Manu Raj Pandey, Jacob Herstein, Abhishek Maiti

Acute myeloid leukemia (AML) continues to pose a major hurdle in hematologic oncology, driven by its genetic complexity and tendency to resist standard therapies. Even with progress in treatment-such as high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT)-outcomes remain unsatisfactory for many …

us (code pays fourni par la source)

Pre-CAR-T pulmonary function test and respiratory comorbidities have limited predictive value for survival, toxicities, and respiratory complications

Yuanli Lei, Muhammad Atif Khan, Aqsa Ashraf, Noha Soror et autres

Abstract Introduction Pre-hematopoietic cell transplantation pulmonary function tests (PFT) are routinely performed for risk-stratification and post-transplant surveillance. Their abnormalities are associated with increased risk of pulmonary complications, intensive care admission, and mortality. However, their predictive value in chimeric antigen receptor T-cell (CAR-T) …

us (code pays fourni par la source)

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Brian Andrew Jonas, Sangeetha Venugopal, George Yaghmour, Manu Raj Pandey et autres

Abstract Background: Outcomes for relapsed or refractory (R/R) acute myeloid leukemia (AML) remain poor despite advances in the treatment of AML. MEC, consisting of mitoxantrone, etoposide (ETOP), and cytarabine, is an established regimen for the treatment of R/R AML. Peposertib is a …

us (code pays fourni par la source)

Outpatient administration of idecabtagene vicleucel: Predictors of hospitalization and impact on survival outcomes

Aqsa Ashraf, Noha Soror, Ayesha Aijaz, Muhammad Salman Faisal et autres

Abstract Introduction: Idecabtagene vicleucel (Ide-cel) is a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) and is approved by FDA after at least two lines of therapy (Otero et al. 2023). Early clinical trials, including the KarMMa …

us (code pays fourni par la source)

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Eric J. Huselton, Uma Borate, John Leonard Reagan, Richard F. Little et autres

Abstract Background Acute myeloid leukemia (AML) with an IDH2 mutation represents a distinct molecular subtype with sensitivity to venetoclax-based regimens. In the VIALE A trial, 56% of IDH2 mutant patients treated with azacitidine and venetoclax achieved a complete remission (CR) and 50% …

us, gb (code pays fourni par la source)

The role of interim bone marrow assessments in acute myeloid leukemia – A systematic review and meta-analysis

Yuanli Lei, Zhiting Tang, Jessica A. Reese, OMER HASSAN JAMY et autres

us (code pays fourni par la source)

SUN-084 A Case of Central Diabetes Insipidus Following CAR-T Cell Therapy

John Lung, Manu Raj Pandey, Emma Punni, Itivrita Goyal

Abstract Disclosure: J. Lung: None. N. Bang: None. M. Pandey: None. E. Punni: None. I. Goyal: None. Introduction: Chimeric antigen receptor T-cell therapy (CAR-T) cell therapy is used for treatment for several lymphomas and leukemias. However, endocrine-related toxicities are reported rarely. We …

us (code pays fourni par la source)

INTENSIVE CARE UNIT ADMISSION RATE AND OUTCOMES IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Maryam Bibi, ADOLFO DIAZ BARBA, Mohammad Jamil, Muhammad Asif et autres

A META-ANALYSIS ON SURVIVAL AFTER LUNG TRANSPLANTATION FOR MANAGEMENT OF BRONCHIOLITIS OBLITERANS SYNDROME SECONDARY TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Maryam Bibi, ADOLFO DIAZ BARBA, Mohammad Jamil, Muhammad Asif et autres

Physician Advocacy for Hematopoietic Cell Transplantation and Cell Therapy: Overcoming Challenges to Reduce Disparities and Improve Outcomes for Patients

Nima Ghalehsari, Manu Raj Pandey, Jeffery J. Auletta, Ellie Beaver et autres

us (code pays fourni par la source)